Modality
Bispecific Ab
MOA
IL-13i
Target
CD47
Pathway
Notch
OCDCMLEpilepsy
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
~Mar 2019
→ ~Jun 2020
NDA/BLA
Sep 2020
→ Jun 2031
NDA/BLACurrent
NCT04199106
945 pts·Epilepsy
2020-09→2031-06·Recruiting
945 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-235.2y awayPh3 Readout· Epilepsy
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-06-23 · 5.2y away
Epilepsy
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04199106 | NDA/BLA | Epilepsy | Recruiting | 945 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |